Bisphenol A Subcommittee of the Science Board to the Food and Drug Administration; Notice of Meeting, 47957 [E8-18864]

Download as PDF Federal Register / Vol. 73, No. 159 / Friday, August 15, 2008 / Notices Officer. E-mail address: infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection. The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication. Dated: August 7, 2008. Janean Chambers, Reports Clearance Officer. [FR Doc. E8–18790 Filed 8–14–08; 8:45 am] BILLING CODE 4184–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2008–N–0038] Bisphenol A Subcommittee of the Science Board to the Food and Drug Administration; Notice of Meeting AGENCY: Food and Drug Administration, HHS. mstockstill on PROD1PC66 with NOTICES ACTION: Notice. This notice announces the following meeting: Bisphenol A (BPA) Subcommittee of the Science Board to the Food and Drug Administration (FDA) meeting. The topic to be discussed is the draft assessment of BPA for use in food contact applications. The Subcommittee will hear and discuss the draft assessment of BPA for use in food contact applications, including oral presentations from the public. Date and Time: The meeting will be held on September 16, 2008, at 9 a.m. to 3:30 p.m. Location: Hilton Washington, WashingtonDC/Rockville Executive Meeting Center, Plaza Ballroom, 1750 Rockville Pike, Rockville, MD 20852. ˜ Contact Person: Carlos Pena, Office of Science and Health Coordination, Office of the Commissioner (HF–33), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, rm. 14B–08) Rockville, MD 20857, 301–827–3340, or VerDate Aug<31>2005 19:03 Aug 14, 2008 Jkt 214001 ˜ by e-mail: Carlos.Pena@fda.hhs.gov or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512603. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting. Agenda: The Subcommittee will hear and discuss the draft assessment of BPA for use in food contact applications, including oral presentations from the public. FDA’s draft assessment of BPA and FDA’s charge to the Subcommittee will be posted on or after August 15, 2008, on FDA’s Web site at https:// www.fda.gov/ohrms/dockets/ac/ acmenu.htm, click on the year 2008 and scroll down to the appropriate advisory committee link. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at https://www.fda.gov/ohrms/ dockets/ac/acmenu.htm, click on the year 2008 and scroll down to the appropriate advisory committee link. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the Subcommittee. Written submissions may be made to the contact person on or before September 12, 2008. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 noon and between approximately 1 p.m. and 2 p.m. on September 16, 2008. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 4, 2008. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 47957 FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by September 5, 2008. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Dr. Carlos ˜ Pena at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at https://www.fda.gov/oc/advisory/ default.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: August 11, 2008. Jeffrey Shuren, Associate Commissioner for Policy and Planning. [FR Doc. E8–18864 Filed 8–14–08; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Services Subcommittee of the Interagency Autism Coordinating Committee (IACC). The purpose of the Services Subcommittee is to review the current state of services and supports for individuals with Autism Spectrum Disorder (ASD) and their families in order to improve these services. The Subcommittee meeting will be conducted as a telephone conference call with presentations on the Web. This meeting is open for the public to call in to listen and to access the Web presentations. The Subcommittee will report on its meeting at the next meeting of the IACC on November 21, 2008. Name of Committee: Interagency Autism Coordinating Committee (IACC). E:\FR\FM\15AUN1.SGM 15AUN1

Agencies

[Federal Register Volume 73, Number 159 (Friday, August 15, 2008)]
[Notices]
[Page 47957]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-18864]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-N-0038]


Bisphenol A Subcommittee of the Science Board to the Food and 
Drug Administration; Notice of Meeting

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    This notice announces the following meeting: Bisphenol A (BPA) 
Subcommittee of the Science Board to the Food and Drug Administration 
(FDA) meeting. The topic to be discussed is the draft assessment of BPA 
for use in food contact applications. The Subcommittee will hear and 
discuss the draft assessment of BPA for use in food contact 
applications, including oral presentations from the public.
    Date and Time: The meeting will be held on September 16, 2008, at 9 
a.m. to 3:30 p.m.
    Location: Hilton Washington, WashingtonDC/Rockville Executive 
Meeting Center, Plaza Ballroom, 1750 Rockville Pike, Rockville, MD 
20852.
    Contact Person: Carlos Pe[ntilde]a, Office of Science and Health 
Coordination, Office of the Commissioner (HF-33), Food and Drug 
Administration, 5600 Fishers Lane, (for express delivery, rm. 14B-08) 
Rockville, MD 20857, 301-827-3340, or by e-mail: 
Carlos.Pe[ntilde]a@fda.hhs.gov or FDA Advisory Committee Information 
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 
3014512603. Please call the Information Line for up-to-date information 
on this meeting. A notice in the Federal Register about last minute 
modifications that impact a previously announced advisory committee 
meeting cannot always be published quickly enough to provide timely 
notice. Therefore, you should always check the agency's Web site and 
call the appropriate advisory committee hot line/phone line to learn 
about possible modifications before coming to the meeting.
    Agenda: The Subcommittee will hear and discuss the draft assessment 
of BPA for use in food contact applications, including oral 
presentations from the public. FDA's draft assessment of BPA and FDA's 
charge to the Subcommittee will be posted on or after August 15, 2008, 
on FDA's Web site at https://www.fda.gov/ohrms/dockets/ac/acmenu.htm, 
click on the year 2008 and scroll down to the appropriate advisory 
committee link.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at https://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on 
the year 2008 and scroll down to the appropriate advisory committee 
link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the Subcommittee. 
Written submissions may be made to the contact person on or before 
September 12, 2008. Oral presentations from the public will be 
scheduled between approximately 11 a.m. and 12 noon and between 
approximately 1 p.m. and 2 p.m. on September 16, 2008. Those desiring 
to make formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before September 4, 2008. Time allotted 
for each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by September 5, 2008.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Dr. Carlos 
Pe[ntilde]a at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at https://www.fda.gov/oc/advisory/
default.htm for procedures on public conduct during advisory committee 
meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 11, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-18864 Filed 8-14-08; 8:45 am]
BILLING CODE 4160-01-S

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.